{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:27:35Z","timestamp":1793273255310,"version":"4.5.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neurot.2024.e00462","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:54:19Z","timestamp":1728622459000},"page":"e00462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Microbiome-based therapeutics for Parkinson's disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Adam M.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Krout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria C.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2016.10.027","article-title":"The central nervous system and the gut microbiome","volume":"167","author":"Sharon","year":"2016","journal-title":"Cell"},{"issue":"7402","key":"10.1016\/j.neurot.2024.e00462_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature11234","article-title":"Structure, function and diversity of the healthy human microbiome","volume":"486","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.chom.2020.06.008","article-title":"The microbiome as a modifier of neurodegenerative disease risk","volume":"28","author":"Fang","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40035-023-00392-8","article-title":"Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00462_bib5","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/ene.13398","article-title":"More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota","volume":"24","author":"Mertsalmi","year":"2017","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy. 1817","volume":"14","author":"Parkinson","year":"2002","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2024.e00462_bib7","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S1353-8020(11)70062-1","article-title":"Pre-motor features of Parkinson's disease: the honolulu-Asia aging study experience","volume":"18","author":"Ross","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.57.3.456","article-title":"Frequency of bowel movements and the future risk of Parkinson's disease","volume":"57","author":"Abbott","year":"2001","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.neurot.2024.e00462_bib9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.0b013e3181bf992f","article-title":"Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort","volume":"73","author":"Uc","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00462_bib10","article-title":"Inflammatory bowel disease and risk of Parkinson's disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals","volume":"10","author":"Li","year":"2023","journal-title":"Front Med"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00462_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol"},{"issue":"465","key":"10.1016\/j.neurot.2024.e00462_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5280","article-title":"The vermiform appendix impacts the risk of developing Parkinson's disease","volume":"10","author":"Killinger","year":"2018","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J\u00a0Neural Trans"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00462_bib14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/mds.25952","article-title":"Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease","volume":"29","author":"Dijkstra","year":"2014","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","article-title":"Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation","volume":"7","author":"Romano","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41531-024-00724-z","article-title":"Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease","volume":"10","author":"Nishiwaki","year":"2024","journal-title":"NPJ Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.29300","article-title":"Integrated multi-cohort analysis of the Parkinson's disease gut metagenome","volume":"38","author":"Boktor","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2024.e00462_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.irn.2022.07.007","article-title":"The many genomes of Parkinson's disease","volume":"167","author":"Payami","year":"2022","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00797-20","article-title":"Short-chain fatty acid-producing gut microbiota is decreased in Parkinson's disease but not in rapid-eye-movement sleep behavior disorder","volume":"5","author":"Nishiwaki","year":"2020","journal-title":"mSystems"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib20","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1038\/s41467-023-38248-4","article-title":"Gut microbiome dysbiosis across early Parkinson's disease, REM sleep behavior disorder and their first-degree relatives","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/mds.27105","article-title":"The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder","volume":"33","author":"Heintz-Buschart","year":"2018","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib22","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ana.26128","article-title":"Gut microbiome signatures of risk and prodromal markers of Parkinson disease","volume":"90","author":"Heinzel","year":"2021","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ana.26719","article-title":"Metagenomics of the gut microbiome in Parkinson's disease: prodromal changes","volume":"94","author":"Palacios","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00462_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.875261","article-title":"The gut microbiome in Parkinson's disease: a longitudinal study of the impacts on disease progression and the use of device-assisted therapies","volume":"14","author":"Lubomski","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41531-022-00328-5","article-title":"Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease","volume":"8","author":"Nishiwaki","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12060739","article-title":"Not just a snapshot: an Italian longitudinal evaluation of stability of gut microbiota findings in Parkinson's disease","volume":"12","author":"Cerroni","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.neurot.2024.e00462_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","article-title":"Gut microbiota in Parkinson's disease: temporal stability and relations to disease progression","volume":"44","author":"Aho","year":"2019","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00462_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187307","article-title":"Progression of Parkinson's disease is associated with gut dysbiosis: two-year follow-up study","volume":"12","author":"Minato","year":"2017","journal-title":"PLoS One"},{"issue":"s2","key":"10.1016\/j.neurot.2024.e00462_bib29","first-page":"S281","article-title":"Brain-first versus gut-first Parkinson's disease: a hypothesis","volume":"9","author":"Borghammer","year":"2019","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.neurot.2024.e00462_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106101","article-title":"Brain-first vs. body-first Parkinson's disease: an update on recent evidence","volume":"122","author":"Horsager","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib31","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1038\/s41467-024-49402-x","article-title":"Disease progression modelling reveals heterogeneity in trajectories of Lewy-type alpha-synuclein pathology","volume":"15","author":"Mastenbroek","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib32","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1038\/s41467-022-34667-x","article-title":"Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms","volume":"13","author":"Wallen","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib33","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib34","first-page":"1479","article-title":"Effects of gut microbiota alterations on motor, gastrointestinal, and behavioral phenotype in a mouse model of Parkinson's disease","volume":"12","author":"Radisavljevic","year":"2022","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.neurot.2024.e00462_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuro.2014.05.009","article-title":"Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats","volume":"44","author":"Bisht","year":"2014","journal-title":"Neurotoxicology"},{"issue":"25","key":"10.1016\/j.neurot.2024.e00462_bib36","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease","volume":"98","author":"Du","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pathophys.2017.02.001","article-title":"Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson's disease in rats","volume":"24","author":"Kaur","year":"2017","journal-title":"Pathophysiology"},{"issue":"17","key":"10.1016\/j.neurot.2024.e00462_bib38","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.18632\/aging.102221","article-title":"Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain","volume":"11","author":"Pu","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2020.1866974","article-title":"Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson's disease","volume":"13","author":"Bhattarai","year":"2021","journal-title":"Gut Microb"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib40","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1038\/s41598-020-64797-5","article-title":"Synergistic depletion of gut microbial consortia, but not individual antibiotics, reduces amyloidosis in APPPS1-21 Alzheimer's transgenic mice","volume":"10","author":"Dodiya","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41522-024-00477-w","article-title":"The gut microbiota modulate locomotion via vagus-dependent glucagon-like peptide-1 signaling","volume":"10","author":"Lai","year":"2024","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib42","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.14336\/AD.2023.0309","article-title":"Healthy human fecal microbiota transplantation into mice attenuates MPTP-induced neurotoxicity via AMPK\/SOD2 pathway","volume":"14","author":"Xie","year":"2023","journal-title":"Aging Dis"},{"key":"10.1016\/j.neurot.2024.e00462_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","article-title":"Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: gut microbiota, glial reaction and TLR4\/TNF-alpha signaling pathway","volume":"70","author":"Sun","year":"2018","journal-title":"Brain Behav Immun"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mds.26069","article-title":"Gut microbiota are related to Parkinson's disease and clinical phenotype","volume":"30","author":"Scheperjans","year":"2015","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00462_bib45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/mds.26307","article-title":"Colonic bacterial composition in Parkinson's disease","volume":"30","author":"Keshavarzian","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41598-018-19646-x","article-title":"Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice","volume":"8","author":"Choi","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/gutjnl-2018-316844","article-title":"Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice","volume":"68","author":"Perez-Pardo","year":"2019","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib48","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.celrep.2015.09.044","article-title":"Antagonizing neuronal toll-like receptor 2 prevents synucleinopathy by activating autophagy","volume":"13","author":"Kim","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib49","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/ncomms2534","article-title":"Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia","volume":"4","author":"Kim","year":"2013","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12017-019-08539-5","article-title":"Chronic mild gut inflammation accelerates brain neuropathology and motor dysfunction in alpha-synuclein mutant mice","volume":"21","author":"Kishimoto","year":"2019","journal-title":"NeuroMolecular Med"},{"issue":"7766","key":"10.1016\/j.neurot.2024.e00462_bib51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","article-title":"Intestinal infection triggers Parkinson's disease-like symptoms in Pink1(-\/-) mice","volume":"571","author":"Matheoud","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2024.e00462_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/febs.17023","article-title":"Microbial amyloids in neurodegenerative amyloid diseases","author":"Sampson","year":"2023","journal-title":"FEBS J"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00462_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028032","article-title":"Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease","volume":"6","author":"Forsyth","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","article-title":"Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats","volume":"128","author":"Holmqvist","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-019-02040-w","article-title":"Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats","volume":"138","author":"Van Den Berge","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41593-020-0589-7","article-title":"Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice","volume":"23","author":"Challis","year":"2020","journal-title":"Nat Neurosci"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00462_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006654","article-title":"The role of microbial amyloid in neurodegeneration","volume":"13","author":"Friedland","year":"2017","journal-title":"PLoS Pathog"},{"issue":"34","key":"10.1016\/j.neurot.2024.e00462_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106504118","article-title":"Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.neurot.2024.e00462_bib59","article-title":"Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged fischer 344 rats and Caenorhabditis elegans","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib60","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53111","article-title":"A\u00a0gut bacterial amyloid promotes alpha-synuclein aggregation and motor impairment in mice","volume":"9","author":"Sampson","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.neurot.2024.e00462_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105780","article-title":"Gut microbial metabolites in Parkinson's disease: association with lifestyle, disease characteristics, and treatment status","volume":"170","author":"Voigt","year":"2022","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13050790","article-title":"Trimethylamine N-oxide exacerbates neuroinflammation and motor dysfunction in an acute MPTP mice model of Parkinson's disease","volume":"13","author":"Quan","year":"2023","journal-title":"Brain Sci"},{"issue":"6445","key":"10.1016\/j.neurot.2024.e00462_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6323","article-title":"Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism","volume":"364","author":"Maini Rekdal","year":"2019","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib64","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","article-title":"Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease","volume":"10","author":"van Kessel","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45953-z","article-title":"A\u00a0novel pathway of levodopa metabolism by commensal Bifidobacteria","volume":"13","author":"Cirstea","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.celrep.2019.12.078","article-title":"Probiotic Bacillus subtilis protects against alpha-synuclein aggregation in C. elegans","volume":"30","author":"Goya","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bbi.2020.10.014","article-title":"Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway","volume":"91","author":"Sun","year":"2021","journal-title":"Brain Behav Immun"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00462_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076794","article-title":"Neuroprotective effects of Lactobacillus plantarum PS128 in a mouse model of Parkinson's disease: the role of gut microbiota and MicroRNAs","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Suppl 6","key":"10.1016\/j.neurot.2024.e00462_bib69","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.1093\/cid\/ciad644","article-title":"Review article: gastroenterology and Clostridium difficile infection: past, present, and future","volume":"77","author":"Kelly","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00462_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae309","article-title":"Recurrent clostridioides difficile infection and outcome of fecal microbiota transplantation use: a population-based assessment","volume":"11","author":"Mehta","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/j.gastro.2020.09.038","article-title":"Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry","volume":"160","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00462_bib73","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.neurot.2024.e00462_bib74","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2022.16476","article-title":"Extended follow-up of microbiome therapeutic SER-109 through 24 Weeks for recurrent clostridioides difficile infection in a randomized clinical trial","volume":"328","author":"Cohen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2024.e00462_bib75","article-title":"Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"141","author":"Porcari","year":"2023","journal-title":"J\u00a0Autoimmun"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041016","article-title":"Fecal microbiota transplantation in inflammatory bowel disease","volume":"11","author":"Boicean","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5217\/ir.2023.00085","article-title":"The practice of fecal microbiota transplantation in inflammatory bowel disease","volume":"22","author":"Arora","year":"2024","journal-title":"Intest Res"},{"issue":"720","key":"10.1016\/j.neurot.2024.e00462_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2750","article-title":"Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement","volume":"15","author":"Woodworth","year":"2023","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib79","first-page":"150","article-title":"Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis","volume":"35","author":"Rapoport","year":"2022","journal-title":"Ann Gastroenterol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12974-023-02782-1","article-title":"Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"20","author":"Yu","year":"2023","journal-title":"J\u00a0Neuroinflammation"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib81","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s13311-023-01420-1","article-title":"Fecal microbiota transplantation from aged mice render recipient mice resistant to MPTP-induced nigrostriatal degeneration via a neurogenesis-dependent but inflammation-independent manner","volume":"20","author":"Qiao","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00462_bib82","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11064-021-03411-0","article-title":"Fecal microbiota transplantation exerts a protective role in MPTP-induced Parkinson's disease via the TLR4\/PI3K\/AKT\/NF-kappaB pathway stimulated by alpha-synuclein","volume":"46","author":"Zhong","year":"2021","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib83","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40168-021-01107-9","article-title":"Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis","volume":"9","author":"Zhao","year":"2021","journal-title":"Microbiome"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","article-title":"Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation","volume":"20","author":"Kuai","year":"2021","journal-title":"Microb Cell Fact"},{"issue":"35","key":"10.1016\/j.neurot.2024.e00462_bib85","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022035","article-title":"Fecal microbiota transplantation therapy for Parkinson's disease: a preliminary study","volume":"99","author":"Xue","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.neurot.2024.e00462_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1104759","article-title":"Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study","volume":"14","author":"DuPont","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2284247","article-title":"Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design","volume":"15","author":"Cheng","year":"2023","journal-title":"Gut Microb"},{"key":"10.1016\/j.neurot.2024.e00462_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102563","article-title":"Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"71","author":"Bruggeman","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00462_bib89","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jamaneurol.2024.2305","article-title":"Fecal microbiota transplantation for treatment of Parkinson disease: a randomized clinical trial","volume":"81","author":"Scheperjans","year":"2024","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00462_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005047","article-title":"Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review","volume":"4","author":"McFarland","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurot.2024.e00462_bib91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroscience.2022.11.004","article-title":"Chronic treatment with the probiotics lacticaseibacillus rhamnosus GG and Bifidobacterium lactis BB12 attenuates motor impairment, striatal microglial activation, and dopaminergic loss in rats with 6-Hydroxydopamine-induced hemiparkinsonism","volume":"507","author":"Cuevas-Carbonell","year":"2022","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib92","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.18632\/aging.102927","article-title":"Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models","volume":"12","author":"Castelli","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65061-w","article-title":"A\u00a0neurotherapeutic approach with Lacticaseibacillus rhamnosus E9 on gut microbiota and intestinal barrier in MPTP-induced mouse model of Parkinson's disease","volume":"14","author":"Aktas","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1022879","article-title":"Probiotic Pediococcus pentosaceus ameliorates MPTP-induced oxidative stress via regulating the gut microbiota-gut-brain axis","volume":"12","author":"Pan","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10040206","article-title":"Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's disease","volume":"10","author":"Hsieh","year":"2020","journal-title":"Brain Sci"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib96","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1212\/WNL.0000000000010998","article-title":"Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study","volume":"96","author":"Tan","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib97","first-page":"117","article-title":"Use of probiotics for the treatment of constipation in Parkinson's disease patients","volume":"57","author":"Cassani","year":"2011","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00462_bib98","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","article-title":"Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT","volume":"87","author":"Barichella","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00462_bib99","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2147\/CIA.S106284","article-title":"Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope?","volume":"11","author":"Georgescu","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41531-022-00327-6","article-title":"Probiotics synergized with conventional regimen in managing Parkinson's disease","volume":"8","author":"Sun","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00462_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244680","article-title":"Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: a randomised controlled trial","volume":"15","author":"Ibrahim","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00462_bib102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.parkreldis.2022.08.022","article-title":"Probiotics for constipation and gut microbiota in Parkinson's disease","volume":"103","author":"Du","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00462_bib103","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.1039\/D3FO00728F","article-title":"Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease","volume":"14","author":"Yang","year":"2023","journal-title":"Food Funct"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib104","article-title":"Efficacy of probiotics in improving motor function and alleviating constipation in Parkinson's disease: a randomized controlled trial","volume":"22","author":"Ghalandari","year":"2023","journal-title":"Iran J Pharm Res (IJPR)"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00462_bib105","first-page":"289","article-title":"The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: a randomized, double-blind, PlaceboControlled trial","volume":"21","author":"Borzabadi","year":"2018","journal-title":"Arch Iran Med"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib106","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.clnu.2018.05.018","article-title":"Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Tamtaji","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.neurot.2024.e00462_bib107","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2019.00969","article-title":"Probiotics may have beneficial effects in Parkinson's disease: in vitro evidence","volume":"10","author":"Magistrelli","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00462_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223309","article-title":"Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: a meta-analysis of randomized controlled trials","volume":"14","author":"Yu","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neurot.2024.e00462_bib109","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","article-title":"Probiotics and prebiotics in intestinal health and disease: from biology to the clinic","volume":"16","author":"Sanders","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib110","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s00394-022-02802-5","article-title":"Validity of food additive maltodextrin as placebo and effects on human gut physiology: systematic review of placebo-controlled clinical trials","volume":"61","author":"Almutairi","year":"2022","journal-title":"Eur J Nutr"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib111","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mds.29279","article-title":"It is as it was: MDS-UPDRS Part III scores cannot Be combined with other parts to give a valid sum","volume":"38","author":"Goetz","year":"2023","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00462_bib112","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/gutjnl-2022-327756","article-title":"Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis","volume":"72","author":"Sun","year":"2023","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib113","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2249.2010.04286.x","article-title":"Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition","volume":"163","author":"Kverka","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib114","first-page":"274","article-title":"Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson's disease - the RESISTA-PD trial","volume":"20","author":"Becker","year":"2022","journal-title":"Dev Reprod Biol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib115","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41467-023-36497-x","article-title":"An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants","volume":"14","author":"Hall","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2024.e00462_bib116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fnagi.2017.00057","article-title":"Promising effects of neurorestorative diets on motor, cognitive, and gastrointestinal dysfunction after symptom development in a mouse model of Parkinson's disease","volume":"9","author":"Perez-Pardo","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00462_bib117","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fnagi.2018.00237","article-title":"Additive effects of levodopa and a neurorestorative diet in a mouse model of Parkinson's disease","volume":"10","author":"Perez-Pardo","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2024.e00462_bib118","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81453","article-title":"A\u00a0prebiotic diet modulates microglial states and motor deficits in alpha-synuclein overexpressing mice","volume":"11","author":"Abdel-Haq","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.neurot.2024.e00462_bib119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","article-title":"Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls","volume":"32","author":"Unger","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13024-021-00427-6","article-title":"Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease","volume":"16","author":"Aho","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2024.e00462_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1388401","article-title":"Buty and the beast: the complex role of butyrate in Parkinson's disease","volume":"15","author":"Elford","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020376","article-title":"Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's disease","volume":"9","author":"Hegelmaier","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00462_bib123","article-title":"Effectiveness of the combination of probiotic supplementation on motor symptoms and constipation in Parkinson's disease","volume":"15","author":"Alexoudi","year":"2023","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00462_bib124","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.neuropharm.2012.01.026","article-title":"The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD","volume":"62","author":"Rane","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurot.2024.e00462_bib125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbr.2015.05.052","article-title":"Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity","volume":"291","author":"Sharma","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.neurot.2024.e00462_bib126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jnutbio.2019.03.021","article-title":"Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity","volume":"69","author":"Srivastav","year":"2019","journal-title":"J\u00a0Nutr Biochem"},{"key":"10.1016\/j.neurot.2024.e00462_bib127","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuroscience.2013.04.037","article-title":"Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease","volume":"246","author":"St Laurent","year":"2013","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib128","first-page":"1","article-title":"Dietary interventions in Parkinson's disease","volume":"14","author":"van der Berg","year":"2024","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"3-4","key":"10.1016\/j.neurot.2024.e00462_bib129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000450855","article-title":"Gene-environment interaction in Parkinson's disease: coffee, ADORA2A, and CYP1A2","volume":"47","author":"Chuang","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00462_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002237","article-title":"Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee","volume":"7","author":"Hamza","year":"2011","journal-title":"PLoS Genet"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00462_bib131","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/mds.21706","article-title":"Coffee and tea consumption and the risk of Parkinson's disease","volume":"22","author":"Hu","year":"2007","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib132","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mds.27577","article-title":"The association between lifestyle factors and Parkinson's disease progression and mortality","volume":"34","author":"Paul","year":"2019","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib133","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/mds.21782","article-title":"Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk","volume":"23","author":"Powers","year":"2008","journal-title":"Mov Disord"},{"issue":"24","key":"10.1016\/j.neurot.2024.e00462_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/nu14245373","article-title":"The interaction of polyphenols and the gut microbiota in neurodegenerative diseases","volume":"14","author":"Zhang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.neurot.2024.e00462_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.887407","article-title":"Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease","volume":"12","author":"Cui","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib136","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29744-5","article-title":"Gut microbiota modulation accounts for the neuroprotective properties of anthocyanins","volume":"8","author":"Marques","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.689456","article-title":"Polyphenol-mediated gut microbiota modulation: toward prebiotics and further","volume":"8","author":"Rodriguez-Daza","year":"2021","journal-title":"Front Nutr"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib138","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40168-021-01115-9","article-title":"Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis","volume":"9","author":"Wu","year":"2021","journal-title":"Microbiome"},{"issue":"15","key":"10.1016\/j.neurot.2024.e00462_bib139","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.0b013e31824f7fc4","article-title":"Habitual intake of dietary flavonoids and risk of Parkinson disease","volume":"78","author":"Gao","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00462_bib140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.brainres.2008.02.107","article-title":"Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice","volume":"1214","author":"Rezai-Zadeh","year":"2008","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib141","first-page":"4883","article-title":"(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol Med Rep"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00462_bib142","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jocn.2010.01.042","article-title":"Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"17","author":"Kim","year":"2010","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib143","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/mmi.13379","article-title":"The green tea polyphenol EGCG inhibits E. coli biofilm formation by impairing amyloid curli fibre assembly and downregulating the biofilm regulator CsgD via the sigma(E) -dependent sRNA RybB","volume":"101","author":"Serra","year":"2016","journal-title":"Mol Microbiol"},{"issue":"Pt 3","key":"10.1016\/j.neurot.2024.e00462_bib144","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1042\/bj3220859","article-title":"Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction","volume":"322","author":"Tomiyama","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.neurot.2024.e00462_bib145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2011.04.019","article-title":"Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation","volume":"1395","author":"Bi","year":"2011","journal-title":"Brain Res"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00462_bib146","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00210-023-02435-3","article-title":"Doxycycline inhibits dopaminergic neurodegeneration through upregulation of axonal and synaptic proteins","volume":"396","author":"do Amaral","year":"2023","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib147","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3892\/mmr.2014.2480","article-title":"Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway","volume":"10","author":"Bi","year":"2014","journal-title":"Mol Med Rep"},{"issue":"11","key":"10.1016\/j.neurot.2024.e00462_bib148","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","article-title":"Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils","volume":"11","author":"Li","year":"2004","journal-title":"Chem Biol"},{"key":"10.1016\/j.neurot.2024.e00462_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/srep41755","article-title":"Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards non-toxic parallel beta-sheet structured species","volume":"7","author":"Gonzalez-Lizarraga","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.brainres.2006.12.074","article-title":"Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer","volume":"1139","author":"Xu","year":"2007","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib151","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/TA.0b013e31825133c0","article-title":"The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury","volume":"73","author":"Wei","year":"2012","journal-title":"J\u00a0Trauma Acute Care Surg"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib152","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.immuni.2020.09.011","article-title":"Tetracycline antibiotics induce host-dependent disease tolerance to infection","volume":"54","author":"Colaco","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.neurot.2024.e00462_bib153","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.alcohol.2024.01.006","article-title":"Ceftriaxone alters the gut microbiome composition and reduces alcohol intake in male and female Sprague-Dawley rats","volume":"120","author":"Duclot","year":"2024","journal-title":"Alcohol"},{"issue":"4","key":"10.1016\/j.neurot.2024.e00462_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095476","article-title":"Short-term effect of antibiotics on human gut microbiota","volume":"9","author":"Panda","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.neurot.2024.e00462_bib155","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3949\/ccjm.85gr.18005","article-title":"Our missing microbes: short-term antibiotic courses have long-term consequences","volume":"85","author":"Blaser","year":"2018","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib156","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/s41467-022-29919-9","article-title":"Evolution of the murine gut resistome following broad-spectrum antibiotic treatment","volume":"13","author":"de Nies","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.neurot.2024.e00462_bib157","article-title":"Antibiotic consumption patterns in European countries are associated with the prevalence of Parkinson's disease; the possible augmenting role of the narrow-spectrum penicillin","volume":"11","author":"Ternak","year":"2022","journal-title":"Antibiotics (Basel)."},{"issue":"3","key":"10.1016\/j.neurot.2024.e00462_bib158","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.27924","article-title":"Antibiotic exposure and risk of Parkinson's disease in Finland: a nationwide case-control study","volume":"35","author":"Mertsalmi","year":"2020","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib159","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","article-title":"Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice","volume":"42","author":"Gencay","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109930","article-title":"Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome","volume":"37","author":"Lam","year":"2021","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00462_bib161","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.chom.2019.05.001","article-title":"Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model","volume":"25","author":"Hsu","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.neurot.2024.e00462_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29173-4","article-title":"Parkinson's disease and bacteriophages as its overlooked contributors","volume":"8","author":"Tetz","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00462_bib163","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13099-016-0109-1","article-title":"Bacteriophage infections of microbiota can lead to leaky gut in an experimental rodent model","volume":"8","author":"Tetz","year":"2016","journal-title":"Gut Pathog"},{"key":"10.1016\/j.neurot.2024.e00462_bib164","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3389\/fmicb.2017.02239","article-title":"Prion-like domains in phagobiota","volume":"8","author":"Tetz","year":"2017","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib165","first-page":"307","article-title":"Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics","volume":"128","author":"Smith","year":"1982","journal-title":"J\u00a0Gen Microbiol"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib166","first-page":"175","article-title":"Bacteriophage treatment of suppurative skin infections","volume":"35","author":"Cislo","year":"1987","journal-title":"Arch Immunol Ther Exp"},{"issue":"2","key":"10.1016\/j.neurot.2024.e00462_bib167","first-page":"134","article-title":"Protection with bacteriophage KO1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice","volume":"42","author":"Malik","year":"2009","journal-title":"J\u00a0Microbiol Immunol Infect"},{"issue":"5","key":"10.1016\/j.neurot.2024.e00462_bib168","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"issue":"6629","key":"10.1016\/j.neurot.2024.e00462_bib169","doi-asserted-by":"crossref","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"issue":"8026","key":"10.1016\/j.neurot.2024.e00462_bib170","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41586-024-07681-w","article-title":"In situ targeted base editing of bacteria in the mouse gut","volume":"632","author":"Brodel","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2024.e00462_bib171","article-title":"Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson\u2019s disease","author":"Payami","year":"2024","journal-title":"medRxiv"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:24:04Z","timestamp":1731417844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":171,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1878747924001491"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00462","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbiome-based therapeutics for Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00462"}}